Apalutamide is the first non-metastatic, castration-resistant prostate cancer (NM-CRPC) treatment approved by the FDA.1 The approval is based upon data from the phase III SPARTAN study, which was presented at the 2018 Genitourinary Cancers Symposium and published in the New England Journal of Medici...